既往靶向磁共振引导前列腺活检阴性者相同病灶重复靶向磁共振引导活检的检出率
回顾性纳入2006年1月至2016年8月间首次靶向磁共振引导前列腺活检(MRGB-1)阴性后行重复活检(MRGB-2)的62例患者共75个病灶,其中63个为再取样、12个为新发病灶。MRGB-2检出临床显著前列腺癌(csPCa,Gleason评分≥3+4)的比例为16/75(21%),再取样病灶中为13/63(21%)。作者认为首次MRGB阴性后重复活检可能使患者获益,尤其在前列腺特异抗原升高且MRI持续怀疑前列腺癌时,并需进一步研究确定阳性重复靶向活检的预测因素。
要点
- 首次靶向磁共振引导前列腺活检阴性后,重复活检的临床显著前列腺癌检出率为16/75(21%)。
- 再取样的63个病灶中13个(21%)在重复活检时检出临床显著前列腺癌。
- 有2例患者在重复活检检出临床显著前列腺癌,而病灶体积在两次活检之间缩小。
核心结论
- 首次MRGB阴性后重复活检的临床显著前列腺癌检出率为16/75(21%),作者认为患者可能从重复活检中获益,尤其在前列腺特异抗原升高且MRI持续怀疑前列腺癌时,并需进一步研究确定阳性重复靶向活检的预测因素。
研究设计与样本
- 回顾性纳入2006年1月至2016年8月间MRGB-1阴性后行MRGB-2的62例患者(中位年龄63岁,四分位距58-66岁),共分析75个取样病灶,其中63个为再取样、12个为新发病灶。
诊断标准与关键数值
- 临床显著前列腺癌定义为Gleason评分≥3+4;MRGB-2在16/75(21%)个病灶中检出临床显著前列腺癌,63个再取样病灶中13个(21%)检出。
局限性
- 原文结论指出需进一步研究以确定阳性重复靶向活检的预测因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: This study's purposes were to determine the yield of repeat direct in-bore magnetic resonance-guided prostate biopsy (MRGB) (MRGB-2) after the first one was found to be negative (MRGB-1), to correlate with clinical parameters, and to present the subgroup analyses of patients with positive repeat biopsies, despite having a negative initial biopsies.
MATERIALS AND METHODS: We retrospectively included patients with MRGB-2 after a negative MRGB-1 both between January 2006 and August 2016. This study included 62 patients (median age, 63 years; interquartile range [IQR], 58-66 years) with 75 sampled lesions during MRGB-2 left for analysis, and 63 lesions were resampled and 12 new lesions were sampled. Included patients had a prostate specific antigen (PSA) at MRGB-1 of 13 ng/mL (IQR, 5.8-20.0) and a PSA at MRGB-2 of 15 ng/mL (IQR, 9.0-22.5). All anonymized magnetic resonance imaging (MRI) data were retrospectively reassessed according to Prostate Imaging-Reporting and Data System version 2 by two radiologists. Images of MRGB were compared to determine whether the same prostate lesion was biopsied during MRGB-1 and MRGB-2. Descriptive statistics were utilized to determine the yield of clinically significant prostate cancer (csPCa) at MRGB-2. Gleason score of ≥ 3 + 4 was considered csPCa.
RESULTS: In 16/75 (21%) lesions csPCa was detected during MRGB-2. Of 63 resampled lesions, 13 (21%) harbored csPCa at MRGB-2. In two patients, csPCa was detected on repeat biopsy, while the volume of the lesion decreased between MRGB-1 and MRGB-2.
CONCLUSION: Patients could benefit from repeat biopsy after negative initial MRGB, especially in the case of increasing PSA values and persisting PCa suspicion in MRI. Further research is needed to establish predictors for positive repeat targeted biopsies.
引用
- Venderink W, Jenniskens SF, Michiel Sedelaar JP, et al. Yield of Repeat Targeted Direct in-Bore Magnetic Resonance-Guided Prostate Biopsy (MRGB) of the Same Lesions in Men Having a Prior Negative Targeted MRGB. Korean J Radiol. 2018. PMID: 29962879. doi:10.3348/kjr.2018.19.4.733
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。